Literature DB >> 8894439

Interleukin-13 and interleukin-4 act as interleukin-6 inducers in human microglial cells.

G Sébire1, J F Delfraissy, J Demotes-Mainard, A Oteifeh, D Emilie, M Tardieu.   

Abstract

The effect of interleukin 4 (IL-4) and IL-13 on IL-6 and IL-1 beta production by human embryonic microglial cells and human peripheral blood monocyte cells (PBMC) was compared. IL-4 or IL-13 increase intra-cellular IL-6 mRNA and IL-6 titres in supernatants of microglial cells whereas they decreased IL-6 production by PBMC tested in the same conditions. IL-4 and IL-13 increased also IL-1 beta production by human microglial cells. Stimulations associating IL-4 or IL-13 and IL-1 beta had an additive effect on IL-6 production by microglial cells, whereas, in the same conditions, an inhibitory effect was observed in PBMC. In contrast, dexamethasone downregulated IL-6 production by microglial cells and PBMC. Finally, IL-1 receptor (IL-1r) type 1 and IL-1r type 2 were detected on human microglial cells but it was demonstrated that IL-13 and IL-4 acted as IL-6 inducers in human microglial cells independently of the IL-1/IL-1r pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894439     DOI: 10.1006/cyto.1996.0085

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  3 in total

1.  High dose methylprednisolone in severe acute transverse myelopathy.

Authors:  G Sébire; H Hollenberg; L Meyer; G Huault; P Landrieu; M Tardieu
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

Review 2.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

3.  Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.

Authors:  Edward Rustamzadeh; Daniel A Vallera; Deborah A Todhunter; Walter C Low; Angela Panoskaltsis-Mortari; Walter A Hall
Journal:  J Neurooncol       Date:  2006-05       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.